Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3217–3240 of 10,536 matching trials from the live ClinicalTrials.gov search.
Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
Acoramidis (AG10)
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Drug · Radiation
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
Active, not recruiting Not applicable Interventional

Remote Hypertension Management for Black Patients

NCT06527794
Conditions
Uncontrolled Hypertension
Interventions
RHYTHM (Remote Hypertension Tracking Help Management), Enhanced usual care (UC)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 85 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Epigenetic Signature for CRC Early Detection

NCT07224854
Conditions
Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation, Cell Free DNA, Early Detection of Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Monrovia, California
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related Tumors
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Interventions
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Santa Barbara, California • New Haven, Connecticut + 23 more
Active, not recruiting No phase listed Observational

Continence Care Registry

NCT04924569
Conditions
Neurogenic Bladder, Non-Neurogenic Bladder
Interventions
Not listed
Lead sponsor
Hollister Incorporated
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Libertyville, Illinois
Active, not recruiting Not applicable Interventional

DBS TaT in Peer-assisted Telemedicine for Hepatitis C

NCT06409169
Conditions
Hepatitis C
Interventions
DBS TaT, Usual Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Adenoid Cystic Carcinoma, Colorectal Cancer
Interventions
RGT-61159, lenvatinib
Drug
Lead sponsor
Rgenta Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers Results available

Gulf War Era Cohort and Biorepository

NCT01803854
Conditions
Gulf War Era Cohort
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
1,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Sleep Health Outcomes for Family Caregivers

NCT07513246
Conditions
Family Caregivers, Sleep
Interventions
Family Caregiver Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Conditions
Alzheimer Disease
Interventions
sabirnetug, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Carlsbad, California • Fullerton, California • Irvine, California + 40 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC

NCT04175041
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Active, not recruiting No phase listed Observational

Cancer Activity and Lifestyle Measurement Study

NCT03961685
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Peposertib
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Conditions
Hepatocellular Carcinoma
Interventions
Cabozantinib, Sorafenib, Atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 26 more
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Buffalo, New York + 2 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Conditions
Batten Disease, CLN6
Interventions
Natural history
Other
Lead sponsor
Emily de los Reyes
Other
Eligibility
2 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
PF-06821497, Docetaxel, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
70
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more